Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Uridine 5'-diphospho-glucuronosyltransferase (UGT) refers to a superfamily of membrane-bound glycosyltransferase enzymes primarily responsible for the glucuronidation reaction, a key Phase II metabolic process. UGTs transfer a glucuronic acid group from UDP-glucuronic acid to various substrates containing oxygen, nitrogen, sulfur, or carboxyl functional groups, including many drugs, toxins, dietary substances, and endogenous molecules such as bilirubin and steroid hormones[1][2][4][6]. This process increases substrate polarity and water solubility, facilitating excretion mainly via urine and bile and enabling the detoxification and clearance of potentially harmful substances from the body[1][2][6]. The human UGTs are divided into several families and subfamilies, most notably UGT1 and UGT2, which feature genetic polymorphisms that influence individual responses to drugs and susceptibility to toxicity[4][7]. Clinically, UGT enzymes play a significant role in drug metabolism, affecting the efficacy and safety of numerous therapeutic agents, including opioids, analgesics, anticonvulsants, antiviral drugs, and more[4][5]. Genetic defects in UGT enzymes (such as UGT1A1) can result in conditions like Crigler-Najjar syndrome and are also implicated in variations in drug response and toxicity[7]. UGTs are further implicated in cancer biology, both by inactivating drug therapies (leading to drug resistance) and potentially influencing cancer progression[5]. Species differences in UGT enzyme activity account for significant variations in drug safety profiles (e.g., cats lack certain UGTs, leading to unique toxicities)[1][4]. Pharmacogenetic testing of UGT genes is increasingly important for predicting drug response, tailoring therapies, and monitoring for adverse reactions[5][7].
Glucuronidation to increase solubility & elimination, Inactivation of drugs, Detoxification of endogenous and exogenous compounds
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uridine 5'-diphospho-glucuronosyltransferase (UGT).